In addition, due to their claimed protective effects in cardiovascular outcome clinical trials, GLP1 RAs and SGLT2 inhibitors have been recently endorsed by the American Diabetes Association as the most appropriate second-line treatment for T2D patients with established atherosclerotic cardiovascular disease (ASCVD) or a high related risk (≥55 years of age with coronary, carotid or lower-extremity artery stenosis >50% or left ventricular hypertrophy), irrespective of glycemic levels [56]. The gene discussed is GLP1R; the disease is diabetes mellitus.